Washington, Reuters. Vaccine maker Novavax Inc (NVAX.O) said on Thursday that it has completed the process of getting its corona vaccine listed for emergency use (EUL) with the World Health Organization (WHO). Is. The company submitted all the modules required for the corona vaccine NVX-CoV2373 to the health agency.
This protein-based corona vaccine was first approved for use in Indonesia. With this, Indonesia became the first country in the world to approve this corona vaccine for emergency use. It is noteworthy that Novavax has adopted a different technology in its vaccine from the vaccine currently in use.
Its vaccine will not require extremely low temperatures, which will boost its supply to the world’s poorer countries. Novavax also said it has applied for emergency permission for its vaccine to be used in the UK, EU countries, Canada, Australia, India and the Philippines.
This two-dose vaccine is made from lab-made replicas of the spike protein, the envelope of the corona virus. This is quite different from m-RNA vaccines such as Pfizer and Moderna, which give the body genetic instructions to make its own spike proteins.
According to Indonesian Epidemiologist Dickie Budiman, allowing emergency use of this vaccine is an important achievement for Indonesia’s Kovid-19 vaccination campaign. He said, the transportation, storage and distribution of this vaccine will be much easier for a country like Indonesia, which has many islands. Let us inform that in Indonesia, more than 1,43,000 people have lost their lives due to the epidemic.
The Indian drug regulator has also given permission to Serum Institute to test US company Novavax’s vaccine on children between the ages of 7 and 11. Serum Institute is making the vaccine of American pharmaceutical company in the name of Kovavax in the country.
Serum has already received approval from the Director General of Medicines of India (DCGI) for its testing on children in the age group of 12 to 17 years. The company has also initially tested it on 100 children and its safety data has also been made available to the drug regulator.
